Étiquette : anxiété

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder, Emily M. LaFrance et al, 2020,

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132   A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]

Lire la suite

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health CareWorkers During the COVID-19 Pandemic. A Randomized Clinical Trial, José Alexandre S. Crippa et al, 2021,

Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health CareWorkers During the COVID-19 Pandemic. A Randomized Clinical Trial José Alexandre S. Crippa, PhD; AntonioW. Zuardi, PhD; Francisco S. Guimarães, PhD; Alline Cristina Campos, PhD; Flávia de Lima Osório, PhD; Sonia Regina Loureiro, PhD; Rafael G. dos Santos, PhD; José Diogo S. Souza, MD; Juliana Mayumi Ushirohira, MD, MSc; Julia Cozar Pacheco, RPh; Rafael Rinaldi Ferreira, PhD, RPh; Karla Cristinne Mancini Costa, MSc; Davi Silveira Scomparin, MSc; Franciele Franco Scarante, MSc; Isabela Pires-Dos-Santos, VMD; Raphael Mechoulam, PhD; Flávio Kapczinski, PhD; Benedito [...]

Lire la suite

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease, Stephanie Martins de Faria et al., 2020

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease Stephanie Martins de Faria, Daiene de Morais Fabrício, Vitor Tumas, Paula Costa Castro, Moacir Antonelli Ponti, Jaime E.C. Hallak, Antonio W. Zuardi, José Alexandre S. Crippa and Marcos Hortes Nisihara Chagas Journal of Psychopharmacology, 2020, 1–8 doi : 10.1177/0269881119895536   Abstract Background : Cannabidiol (CBD) is one of the main components of Cannabis sativa and has anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on anxiety signs and symptoms in patients with Parkinson’s disease (PD). This study aimed to [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan Neuropsychopharmacology Reviews, 2018, 43, 142–154. doi : 10.1038/npp.2017.209; The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are 4550 chemical compounds and 4100 phytocannabinoids [...]

Lire la suite

High-Potency Cannabis Products Linked to Suicidality, Doug Brunk, Medscape.com, February 22, 2021

High-Potency Cannabis Products Linked to Suicidality Doug Brunk Medscape Medical News © 2021 WebMD, LLC February 22, 2021 Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. In the days since recreational sales of marijuana became legal in Colorado in January 2014, concerning trends have emerged among the state's young cannabis users. Dr Paula Riggs According to a report from the Rocky Mountain High Intensity Drug Trafficking Area, between 2014 and 2017, the number of suicides positive for marijuana increased 250% among those aged 10-19 years (from 4 to 14) and 22% among those aged 20 and older (from 118 to 144). "Other states are seeing something [...]

Lire la suite

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients, Diana M. Martinez, MD Medscape .com, 2020

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, décembre 2020

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, décembre 2020. (4e version, décembre 2020....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 29 7 - Cannabinoïdes et Sommeil : 30 - 31 8 - Cannabinoïdes et addiction au Cannabis : 32 - 39 9 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 40 - 54 10 - Cannabinoides et syndrome de Gilles de la Tourette : 58 - 59 11 - Cannabinoides et Hyperactivité [...]

Lire la suite

Troubles anxieux : le CBD peut soulager les symptômes, Kalapa Clinic, 30/06/2020

Troubles anxieux : le CBD peut soulager les symptômes Kalapa Clinic, Barcelone, Espagne By Gesa|30/06/2020   La peur est une réaction naturelle à certaines situations et à certains événements. Elle remplit à la fois une fonction d’avertissement et de protection. Lors d’un trouble anxieux, cependant, elle développe une dynamique propre qui est très stressante pour les personnes concernées. Diverses études et rapports d’expérience indiquent que le cannabinoïde non-psychoactif cannabidiol (CBD) peut soulager leurs symptômes. En Allemagne, le trouble anxieux est la maladie mentale la plus courante, devançant même la dépression. Environ 12 millions de personnes sont touchées, les femmes plus souvent que les hommes (1). Le [...]

Lire la suite

Covid-19 : isolement et conditions de travail favorisent les conduites addictive, MILDECA, Flash info, 19/11/2020

Flash info 19/11/2020 MILDECA Covid-19 : isolement et conditions de travail favorisent les conduites addictives Depuis le premier confinement instauré en mars dernier, l’isolement au travail, l’augmentation des objectifs en matière de performance ainsi que la charge de travail ont joué un rôle dans l’augmentation des consommations de substances psychoactives. C’est ce que montre l’enquête publiée ce jour par la MILDECA et ses partenaires. Pour documenter l’évolution des consommations de substances psychoactives et les conditions de travail en période d’épidémie de Covid-19, la MILDECA et ses partenaires - ANSES, Anact, INRS, OFDT, Santé Publique France et le COCT * - ont commandité une enquête [...]

Lire la suite

The experimental effects of psilocybin on symptoms of anxiety and depression : A meta-analysis, Simon B. Goldberg et al, 2020

The experimental effects of psilocybin on symptoms of anxiety and depression : A meta-analysis Simon B. Goldberg, Brian T. Pace, Christopher R. Nicholas, Charles L. Raison, Paul R. Hutson Psychiatry Research, 2020, 284,  112749 Doi : 10.1016/j.psychres.2020.112749   A B S T R A C T The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled; N = 117), within-group pre-post and pre-follow-up effects on anxiety and depression were large (Hedges’ gs=1.16 to 1.47) and statistically significant. Across three placebo-controlled studies, pre-post placebo-controlled effects were also [...]

Lire la suite